martes, 24 de septiembre de 2019

Flawed trials supported recent approvals of cancer drugs in Europe - STAT

Flawed trials supported recent approvals of cancer drugs in Europe - STAT

Cancer Briefing

STAT Plus: Flawed trials supported half of recent approvals of cancer drugs in Europe, study says

By ED SILVERMAN


ALEX HOGAN/STAT
Randomized, controlled trials accounted for about 90% of pivotal studies from 2009 to 2013 but only 75% of studies from 2014 to 2016.

No hay comentarios: